Clinical trials
Breast clinical trials
Below are recruiting breast clinical trials, each written for real people, not researchers. We’re tracking 2,668 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06373354Recruiting
Comparing 3D mammogram machines for breast cancer screening
This trial compares two types of digital breast tomosynthesis (3D mammogram) systems to see which one makes breast masses and distortions easier to see. If you are a woman getting a routine screening mammogram, you may be able to join.
Houston, TexasAges Any age - NCT07135960Recruiting
Breast motion study after surgery and radiation
This study uses a 3D scanner to measure how your breast moves after surgery and possibly radiation. The results may help doctors improve treatment planning for future patients.
PortsmouthAges 18 years+ - NCT07078604RecruitingPhase 2
Vaccine with chemotherapy for advanced triple-negative breast cancer
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
Seattle, WashingtonAges 18 years+ - NCT06922708Recruiting
Using genetic risk scores to improve breast cancer prevention
This study is testing a new way to use your genetic information (along with your family history) to better understand your personal risk for breast cancer. The goal is to see if giving this risk report to women with higher genetic risk can help them and their doctors make more informed decisions about screening and prevention.
RomaAges 18–79 - NCT06680596Enrolling by invitationPhase 2
Blood test to find T-DXd candidates for breast cancer
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
AmiensAges 18 years+ - NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Springdale, ArkansasAges 18 years+ - NCT05625659Recruiting
Breast cancer screening for dense breasts using new X-ray scans
This trial compares two imaging tests—CESM (a contrast-enhanced mammogram) and DBT (3D mammography)—to see which works best for women with dense breast tissue. It may help improve how early breast changes are found in dense breasts.
Birmingham, AlabamaAges 45–74 - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT06802172Recruiting
Timing meals during cancer treatment for Alaska Native patients
This study tests whether scheduling meals at specific times of day can improve how patients feel during cancer treatment. It is for Alaska Native or American Indian people with certain cancers (rectal, HER2+ or triple negative breast, or other solid tumors) who are receiving neoadjuvant (before surgery) or adjuvant (after surgery) therapy.
Anchorage, AlaskaAges 21 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Chuo Ku, TokyoAges 18 years+ - NCT07723209Recruiting
Radiation after no lymph node sampling in breast cancer
This trial tests whether radiation therapy alone is safe and effective for women 40 and older with early-stage breast cancer who have not had lymph node sampling. It aims to simplify treatment while maintaining good outcomes.
New York, New YorkAges 40 years+ - NCT07318805RecruitingPhase 1
A study of PF-08032562 for advanced solid tumors
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07541079RecruitingPhase 3
Testing a New Breast Cancer Drug for Women Who Can't Tolerate Current Therapy
This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.
Fountain Valley, CaliforniaAges 18 years+ - NCT05592938Recruiting
Partial breast re-irradiation for cancer recurrence
This trial tests a shorter course of radiation to only the part of the breast where cancer has come back. It's for women who had radiation years ago and now have a small new or recurrent tumor that can be removed by surgery.
New York, New YorkAges 18–99 - NCT07661927RecruitingPhase 2
Skipping hormone therapy for low-risk breast cancer
This trial tests whether women with very low-risk, early-stage breast cancer can safely skip hormone therapy after surgery. It is designed for women who are 60 or older and whose cancer shows no spread to lymph nodes and has favorable biology.
AngersAges 60 years+ - NCT05350722Recruiting
Single pre-surgery radiation for low-risk breast cancer
This trial tests a single, shorter course of radiation given before breast surgery for people with low-risk, hormone-receptor–positive breast cancer. It may help treat the breast tumor while reducing the number and length of radiation treatments.
SydneyAges 40 years+ - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT03436069Recruiting
Finding new markers to predict breast cancer outlook
This study looks for new lab “markers” that may help predict how breast cancer is likely to behave over time. Your tumor or health information may be used to find factors that can guide doctors’ predictions.
GrenobleAges 18 years+ - NCT03536897Recruiting
Radiation registry after lumpectomy for certain early breast cancers
This study collects information about people with early-stage, hormone-receptor–positive breast cancer who have a lumpectomy and radiation. It may help doctors understand outcomes after this standard treatment and improve care for future patients.
Columbus, OhioAges 65 years+ - NCT03577197Recruiting
Breast cancer registry for advanced disease in southeast Netherlands
This trial is a cancer registry, meaning your medical information is collected and stored for people with advanced breast cancer. It can help researchers learn from real-world care patterns and outcomes across multiple hospitals in southeast Netherlands.
MaastrichtAges 18 years+ - NCT03643861Recruiting
Radiation after lumpectomy for certain early breast cancers
This trial tests a short, highly targeted radiation plan given in five sessions after lumpectomy for early-stage breast cancer. It may help treat the remaining breast area while aiming to limit exposure to healthy tissue.
Birmingham, AlabamaAges 18–99 - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+
Hear when a new Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast?
- Yes. Clin2 currently lists 2,668 recruiting breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.